Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | President and CFO | April 03, 2023 | April 05, 2023 |
| Q32 Bio Inc.QTTB · Entity 5594 | CFO and President | October 06, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date April 03, 2023 · Filed April 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 30,309 |
Reported balance
After 2023-04-03 transaction · row 1
1 source rowRow 1 · 2023-04-03 · Sale · Disposed 376 · Balance 30,309 F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.03 to $21.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.03 to $21.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Q32 Bio Inc.
Report date October 06, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 137,170 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Sale · Disposed 1,301 · Balance 137,170 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.08 to $8.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.08 to $8.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 25, 2020 Filed Nov 26, 2020 01:31 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 9,781 | $20.07 | $196,304.67 |
DisclosureSEC source: 0001209191-20-060598 · doc4.xml · nonDerivative · entry 5 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.24 inclusive. Read SEC document |
| November 25, 2020 Filed Nov 26, 2020 01:31 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 9,781 | $1.56 | $15,258.36 |
DisclosureSEC source: 0001209191-20-060598 · doc4.xml · nonDerivative · entry 4 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F5 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.33434 to GBP 1.00 as of November 25, 2020. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 01:31 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,189 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001209191-20-060598 · doc4.xml · derivative · entry 6 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,585 Underlying: Ordinary Shares · 17,189 shares Expires 2027-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.33651 to GBP 1.00 as of November 23, 2020. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F7 · derivative.exercise_date: 20% of the shares subject to the option vested on July 24, 2018, 60% of the shares subject to the option will vest each month thereafter in 36 equal monthly installments, and the remaining 20% of the shares subject to the option will vest on the earlier of (i) the fourth anniversary of the grant date and (ii) the date on which the Issuer's board of directors determines that the Issuer has satisfied certain performance vesting milestones, in all cases provided that the Reporting Person remains continuously employed with us through each applicable vesting date. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 01:31 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 213 | $20.38 | $4,340.94 |
DisclosureSEC source: 0001209191-20-060598 · doc4.xml · nonDerivative · entry 3 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.50 inclusive. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 01:31 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 16,976 | $19.82 | $336,464.32 |
DisclosureSEC source: 0001209191-20-060598 · doc4.xml · nonDerivative · entry 2 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213 F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.24 to $20.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4) and (6). Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 01:31 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 17,189 | $1.56 | $26,814.84 |
DisclosureSEC source: 0001209191-20-060598 · doc4.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F2 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.33651 to GBP 1.00 as of November 23, 2020. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 22:02 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0001209191-20-001967 · doc4.xml · derivative · entry 1 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares · 60,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 2, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month therafter. Read SEC document |
| June 28, 2019 Filed Apr 27, 2020 20:45 UTC Amendment | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (Right to Buy) · Derivative | 283,414 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025812 · doc4a.xml · derivative · entry 1 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,414 Underlying: Ordinary Shares · 283,414 shares Expires 2029-06-28 F1 · date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates. F2 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant. F1 · derivative.expiration_date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates. Read SEC document |
| May 28, 2019 Filed May 31, 2019 01:24 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (Right to Buy) · Derivative | 283,414 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001104659-19-032910 · a4.xml · derivative · entry 1 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,414 Underlying: Ordinary Shares · 283,414 shares Expires 2029-05-28 F1 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.